321 related articles for article (PubMed ID: 27096289)
1. Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema.
Puliafito CA; Cousins SW; Bacharach J; Gonzalez VH; Holekamp NM; Merrill PT; Ohr MP; Parrish RK; Riemann CD
Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4 Suppl):S4-S15. PubMed ID: 27096289
[TBL] [Abstract][Full Text] [Related]
2. Introduction.
Puliafito CA
Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4 Suppl):S4. PubMed ID: 27096288
[No Abstract] [Full Text] [Related]
3. Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology.
Ehlers JP; Yeh S; Maguire MG; Smith JR; Mruthyunjaya P; Jain N; Kim LA; Weng CY; Flaxel CJ; Schoenberger SD; Kim SJ
Ophthalmology; 2022 Jan; 129(1):88-99. PubMed ID: 34446301
[TBL] [Abstract][Full Text] [Related]
4. Fluocinolone acetonide implantable device for diabetic retinopathy.
Schwartz SG; Flynn HW
Curr Pharm Biotechnol; 2011 Mar; 12(3):347-51. PubMed ID: 20939799
[TBL] [Abstract][Full Text] [Related]
5. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.
Campochiaro PA; Brown DM; Pearson A; Ciulla T; Boyer D; Holz FG; Tolentino M; Gupta A; Duarte L; Madreperla S; Gonder J; Kapik B; Billman K; Kane FE;
Ophthalmology; 2011 Apr; 118(4):626-635.e2. PubMed ID: 21459216
[TBL] [Abstract][Full Text] [Related]
6. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.
Pearson PA; Comstock TL; Ip M; Callanan D; Morse LS; Ashton P; Levy B; Mann ES; Eliott D
Ophthalmology; 2011 Aug; 118(8):1580-7. PubMed ID: 21813090
[TBL] [Abstract][Full Text] [Related]
7. Fluocinolone acetonide for the treatment of diabetic macular edema.
Veritti D; Sarao V; Diplotti L; Samassa F; Lanzetta P
Expert Opin Pharmacother; 2017 Oct; 18(14):1507-1516. PubMed ID: 28764565
[TBL] [Abstract][Full Text] [Related]
8. Persistent or Recurrent Diabetic Macular Edema After Fluocinolone Acetonide 0.19 mg Implant: Risk Factors and Management.
Cicinelli MV; Rabiolo A; Zollet P; Capone L; Lattanzio R; Bandello F
Am J Ophthalmol; 2020 Jul; 215():14-24. PubMed ID: 32209341
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
[TBL] [Abstract][Full Text] [Related]
10. Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema.
Messenger WB; Beardsley RM; Flaxel CJ
Drug Des Devel Ther; 2013; 7():425-34. PubMed ID: 23737661
[TBL] [Abstract][Full Text] [Related]
11. Fluocinolone acetonide for the treatment of diabetic macular edema.
Haritoglou C; Mayer W; Wolf A
Expert Rev Clin Pharmacol; 2016; 9(3):367-74. PubMed ID: 26681198
[TBL] [Abstract][Full Text] [Related]
12. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
Soubrane G; Behar-Cohen F
J Fr Ophtalmol; 2015 Feb; 38(2):159-67. PubMed ID: 25601517
[TBL] [Abstract][Full Text] [Related]
13. ILUVIEN
Habib MS
Ther Deliv; 2018 Aug; 9(8):547-556. PubMed ID: 29943691
[TBL] [Abstract][Full Text] [Related]
14. Management of diabetic macular edema with intravitreal dexamethasone implants: Expert recommendations using a Delphi-based approach.
Giovannini A; Parravano M; Ricci F; Bandello F
Eur J Ophthalmol; 2019 Jan; 29(1):82-91. PubMed ID: 29882421
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroid use for diabetic macular edema: old fad or new trend?
Stewart MW
Curr Diab Rep; 2012 Aug; 12(4):364-75. PubMed ID: 22581206
[TBL] [Abstract][Full Text] [Related]
16. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
Campochiaro PA; Brown DM; Pearson A; Chen S; Boyer D; Ruiz-Moreno J; Garretson B; Gupta A; Hariprasad SM; Bailey C; Reichel E; Soubrane G; Kapik B; Billman K; Kane FE; Green K;
Ophthalmology; 2012 Oct; 119(10):2125-32. PubMed ID: 22727177
[TBL] [Abstract][Full Text] [Related]
17. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
Syed YY
Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
[TBL] [Abstract][Full Text] [Related]
18. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant.
Ciulla TA; Harris A; McIntyre N; Jonescu-Cuypers C
Expert Opin Pharmacother; 2014 May; 15(7):953-9. PubMed ID: 24661081
[TBL] [Abstract][Full Text] [Related]
19. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.
Totan Y; Güler E; Gürağaç FB
Curr Eye Res; 2016; 41(1):107-13. PubMed ID: 25610946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
